RESEARCH ARTICLE

Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis

Gregorio Spagni\textsuperscript{1}, Laura Todi\textsuperscript{2}, Gabriele Monte\textsuperscript{1}, Mariagrazia Valentini\textsuperscript{2}, Gabriele Di Sante\textsuperscript{2}, Valentina Damato\textsuperscript{1,3}, Mariapaola Marino\textsuperscript{2}, Amelia Evoli\textsuperscript{1,3,}\*\textsuperscript{1,3}, Francesca Lantieri\textsuperscript{4,5} & Carlo Provenzano\textsuperscript{2,6}

\textsuperscript{1}Dipartimento di Neuroscienze, Sezione di Neurologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
\textsuperscript{2}Dipartimento di Medicina e chirurgia traslazionale, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Sezione di Patologia generale, Rome, Italy
\textsuperscript{3}U.O.C. di Neurologia, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Roma, Italy
\textsuperscript{4}Dipartimento di Scienze della Salute, Università degli Studi di Genova, Genova, Italy

Correspondence
Amelia Evoli, Dipartimento di Neuroscienze, Sezione di Neurologia, Università Cattolica del Sacro Cuore, U.O.C. di Neurologia, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy, Tel.: +390630156366; Fax: +3935501909; E-mail: amelia.evoli@unicatt.it

Received: 16 November 2020; Revised: 26 December 2020; Accepted: 13 January 2021

Annals of Clinical and Translational Neurology 2021; 8(3): 656–665
doi: 10.1002/acn3.51309
\*These authors contributed equally to this work.

Abstract

Objective: Genetic factors predisposing to late-onset myasthenia gravis (LOMG) have not been clearly defined yet. However, genome-wide association studies identified Human Leukocyte Antigen (HLA) Class II alleles as a hotspot in this disease subtype. The aim of this study was to analyze the correlations of HLA Class II alleles with clinical data and titin antibodies in this patient subgroup. Methods: This study consecutively enrolled anti-acetylcholine receptor antibody-positive, non-thymoma patients with generalized LOMG. All patients were of Italian ancestry. HLA-DRB1 and -DQB1 genotyping and serum titin antibody testing were performed in this population. Results: A total of 107 patients (females: 28/107, 26.2%; median age of onset: 68 years, range: 50-92) were included. We found a positive association with HLA-DRB1*07 (P = 1.1 \times 10^{-5}), HLA-DRB1*14 (P = 0.0251) and HLA-DQB1*02 (P = 0.0095). HLA-DRB1*03, HLA-DRB1*11, and HLA-DQB1*03 were protective alleles (P = 7.9 \times 10^{-7}, P = 0.0104, and P = 0.0067, respectively). By conditional haplotype analysis, HLA-DRB1*07-DQB1*02 was found to be the major risk haplotype (OR = 4.10; 95% C.I.: 2.80-5.99; P = 6.01 \times 10^{-11}). The mean age at onset was 73.4 years in DRB1*07 homozygotes, 69.7 years in heterozygotes, and 66.6 in non-carriers (P = 0.0488). DRB1*07 carriers and non-carriers did not differ in disease severity and response to therapy. Titin antibodies were detected in 61.4% of the cases, having no association with HLA alleles or specific clinical characteristics. Interpretation: In our study, we identified the HLA DRB1*07-DQB1*02 haplotype as a predisposing factor for the development of generalized LOMG in the Italian population.

Introduction

Myasthenia gravis (MG) is caused by antibodies (Abs) to post-synaptic proteins at the motor end-plate.\textsuperscript{1} Abs to the nicotinic acetylcholine receptor (AChR) are the most common, being detected in around 85% of MG cases.\textsuperscript{1} AChR MG includes three clinical subtypes: early-onset MG (EOMG), late-onset MG (LOMG), generally defined by a cut-off age of 50 years, and thymoma-associated MG.\textsuperscript{2} While EOMG epidemiology has not changed over time, the incidence and prevalence rates of LOMG have steadily increased in the last decades.\textsuperscript{3-6} Given the aging of the general population, it is predictable that LOMG will be even more prevalent in the near future.

It is well-known that LOMG is associated, in about 50% of the cases, with Abs to titin and, to a lesser extent, to the ryanodine receptor (RyR), which are otherwise markers of thymoma.\textsuperscript{7} In earlier studies, titin and RyR Abs were found to be predictive of severe MG with bulbar involvement.\textsuperscript{8,9}
MG subtypes have different Human Leukocyte Antigen (HLA) associations. In Caucasians, EOMG is strongly linked to the extended haplotype 8.1 (A1-B8-DQ2-DR3) across populations,\textsuperscript{10-13} whereas LOMG has been found to be associated with several different Class II alleles.\textsuperscript{12,14-19} Genome-wide association studies (GWAS) confirmed the relevance of HLA Class II region, although no single high-risk variant was identified.\textsuperscript{20,21} Inherent heterogeneity of LOMG, differences in studies on inclusion criteria, age cut-off, patient stratification and sample size, and, not least, the strong linkage disequilibrium among HLA alleles, most likely add to the complexity of this research area.

The aim of this study was to investigate Class II HLA alleles, and their correlation with clinical data and titin Abs, in an Italian cohort of AChR-positive LOMG patients.

**Methods**

**Patient population**

Patients were enrolled in the study during follow-up visits from March 2019 to March 2020 according to the following criteria: (1) generalized AChR-positive MG; (2) absence of thymoma; (3) disease onset ≥50 years of age; (4) Italian ancestry; (5) disease duration ≥2 year.

The clinical diagnosis of MG was confirmed in all patients by positive results of anti-AChR Abs tested by radioimmunoassay (RSR Ltd, Cardiff, UK). Patients' information was collected retrospectively from chart review and prospectively during the study. MG treatment was performed according to accepted guidelines and common clinical practice.\textsuperscript{22} Disease severity and response to treatment were graded with the MG Foundation of America (MGFA) system.\textsuperscript{23} All patients underwent contrast-enhanced chest CT scan to rule out the presence of thymoma. In six patients who underwent thymectomy, histological examination showed no evidence of thymoma.

To verify that the included cohort was representative of our total LOMG population, we performed a preliminary comparative analysis of the main clinical and demographic features of the included cohort versus the total LOMG population treated at our Center (n = 254) (Table S1).

**HLA genotyping and titin antibody testing**

Whole blood samples were collected in EDTA tubes and stored at −20°C until further use. Genomic DNA was extracted using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s instruction and eluted in 100 μL of Tris-EDTA buffer, then stored in aliquots at −20°C.

HLA typing was performed using a reverse line blot method (INNO-LiPA HLA-DRB1 Plus, INNO-LiPA HLA-DQB1 UPDATE assay kits respectively; Innogenetics, Dartford, UK), according to the manufacturer’s instructions.

Patients’ serum samples were stored at −20°C until further use. Sera were tested for titin Abs by a commercially available ELISA kit (DLD Diagnostika, Hamburg, Germany), according to manufacturer’s instructions; positivity was assessed as per instructions. This test gives only a positive/negative result.

**Statistical analysis**

Summary statistics were reported as mean (± standard deviation, SD) or median (with range) for continuous variables and as numbers and percentages for categorical variables. For comparisons between the groups, the Chi-square test, the Fisher’s Exact Test, and the Mann–Whitney U test were performed, as appropriate. Allelic and haplotype associations were analyzed individually versus all the others pooled together, applying the Fisher’s exact test and correcting the p-value for multiple testing with the False Discovery Rate (FDR), Benjamini–Hochberg method with R.\textsuperscript{24} As control population for the allelic associations, we used the one reported by Rendine et al. for random Italian normal subjects genotyped for the DRB1 locus (n = 22114) and for the DQB1 locus (n = 2087),\textsuperscript{25} which corresponds to Italypop5 in Allele Frequency Net Database (http://www.allelefrequencies.net). For the haplotype comparisons, we estimated the haplotype counts for the DRB1 and DQB1 loci from the Allele Frequency Net Database, searching for the haplotype frequency with any DRB1 and any DQB1 allele of the Italypop5 population\textsuperscript{25} available in the database (n = 1447 patients genotyped for DRB1 and DQB1, with a missingness of 2.5%). Reconstruction and estimates of haplotype frequencies for MG patients were performed using PHASE \textsuperscript{2.1}.\textsuperscript{26} To check whether such an unbalanced ratio in the sample size of patients and controls could affect statistical analysis, we simulated 100 control samples with the same size as in cases (214 alleles) for the main association results (i.e. DRB1*07, DQB1*02 and the DRB1*07-DQB1*02 haplotype). Finally, we carried out a conditional analysis focusing on the DRB1*07 and DQB1*02 alleles, and assessed the Linkage Disequilibrium (LD) between the two loci with Plink (http://pngu.mgh.harvard.edu/purcell/plink/).\textsuperscript{27} Furthermore, we performed an association analysis between DRB1*07 and age at onset and between DRB1*07 and titin positivity.
Standard protocol approvals, registrations, and patient consents

All patients provided written informed consent to the study, conducted according to the Helsinki declaration and approved by the Ethic Committee of the Università Cattolica del Sacro Cuore (Rome, Italy) with E.C. protocol number 49886/18 (9024/19, ID:2327).

Results

This study included 107 patients, with age at onset ranging 50 to 92 years (median: 68 years) and a clinical follow-up ranging 2 to 24 years (median: 5 years). Demographic and clinical features are summarized in Table 1. We observed a clear male predominance (female to male ratio = 1:2.8), with females outnumbering males only among patients with onset between 50 and 54 years (Fig. 1). All patients were of Italian ancestry, mostly from Central and Southern Italy (Table S1). The comparative analysis showed that the cohort included in the study was representative of the total LOMG population (n = 254) treated at our Center (Table S1).

Table 1 shows maximum disease severity and treatment. Most patients had mild to moderate disease (MGFA class II-III in 77/107 cases, 71.9%) and 96/107 (89.7%) required immunosuppressive therapy based on steroids and other immunosuppressants, at least at some time during the course of their disease. Six patients (5.6%) underwent thymectomy and the histopathological analysis showed a normal-for-age atrophic thymus in four of them and mild thymic hyperplasia in the other two. At the end of the observation period, 76/107 (71%) patients had achieved a status of “minimal manifestations” or better. Complete stable remission was rare, accounting for 4/107 (3.7%) cases.

HLA-DRB1 allele frequencies of patients and controls are reported in Figure 2A and in Table 2. We found a significant positive association with HLA-DRB1*07 (OR = 2.14; 95% C.I. 1.55-2.94; p = 1.08x10^{-5}), and a weaker one with DRB1*14 (OR = 1.73; 95% C.I. 1.09-2.74; p = 0.0251). We found a negative association with HLA-DRB1*11 (OR = 0.63; 95% C.I.: 0.44-0.91; p = 0.0104) and with HLA-DRB1*03 (OR = 0.23; 95% C.I. 0.10-0.56; p = 7.89x10^{-5}), which had a very low frequency in our cohort (0.0234 vs 0.0936 in controls). The frequency of HLA-DRB1*15 and HLA-DRB1*16 alleles, which were associated with LOMG in other series, did not differ significantly between patients and controls. The associations with DRB1*03 and DRB1*07 were still highly significant after FDR correction was carried out on the 19 alleles detected at the two loci.

HLA-DQB1 allele frequencies in patients and controls are reported in Figure 2B and in Table 2. We found a positive association with HLA-DQB1*02 (OR = 1.57; 95% C.I. 1.13-2.19, P = 0.0095) and a negative one with HLA-DQB1*03 (OR = 0.67; 95% C.I. 0.50-0.90, P = 0.0067). The allele frequency of HLA-DQB1*04, *05, and *06 did not differ between patients and controls.

As shown in Figure 3 and Table S4, haplotype analysis found that HLA-DRB1*07-DQB1*02 was significantly associated with LOMG and conferred the strongest risk in this MG subtype (HLA-DRB1*07-DQB1*02 vs all the other haplotypes: OR = 4.10, 95% C.I. 2.80-5.99, P = 6.01 x 10^{-11}). In addition, we found a positive, although weaker, association with DRB1*14-DQB1*05 (OR = 2.45, 95% C.I. 1.47-4.07, P = 0.0012) and DRB1*15-DQB1*06 (OR = 2.70, 95% C.I. 1.55-4.70, P = 0.0018) haplotypes. These associations were still significant after correction for multiple tests. To verify that the high ratio imbalance between cases and controls could not introduce any bias, and confirm the robustness of our findings, we run 100 simulations on 214 randomly selected alleles with N = 214 (sample size equal to cases).
from the control dataset. We found that all the 100 simulated control sets presented allelic frequencies lower than those detected in the LOMG set (range 0.028-0.093, being 0.052 in the whole control cohort and 0.187 in LOMG) and significant association p-values (range $7.05 \times 10^{-3}$ - $7.76 \times 10^{-8}$ vs $6.01 \times 10^{-11}$ obtained on the whole controls dataset). Using the same approach, we could confirm the association results for DRB1*07 (frequencies in simulated controls between 0.075 and 0.182, 0.125 in the whole control cohort and 0.234 in LOMG; p-values from $6.83 \times 10^{-6}$ to 0.2335, 93 out of 100 $< 0.05$) and, to a lesser extent, for DQB1*02 (frequencies in simulated controls between 0.107 and 0.220, 0.125 in the whole control cohort and 0.224 in LOMG; p-values from 0.0017 to 1.00, 42 out of 100 $P$-values $< 0.05$).

Since both DRB1*07 and DQB1*02 were significant risk alleles in the association analysis, we performed a conditional haplotype analysis on HLA-DRB1*07-DQB1*02 to check whether they were independent risk factors. The association with HLA-DRB1*07 was no longer significant after controlling for DQB1*02, whereas DQB1*02 without the DRB1*07 background showed a weak negative association. The latter finding can be explained by DQB1*02 linkage with the “protective” alleles DRB1*03 and DRB1*11. Overall, these results suggest a major role for the HLA-DRB1*07-DQB1*02 haplotype, making it the main genetic predisposing factor to LOMG in our population. Consistently, the LD between DRB1*07 and DQB1*02 was higher among patients than controls ($D' = 0.771$ vs $D' = 0.341$).

We also found that the DRB1*07 frequency increased in parallel with age at onset: it was higher among patients aged 80 years or older (28.6%) than in those aged 60-79 years (25.4%) or 50-59 years (14.6%). The average age at onset was 73.4 years among homozygotes for DRB1*07, 69.7 among heterozygotes and 66.6 among patients not carrying any DRB1*07 allele ($P = 0.0488$) (Fig S1). The haplotype DRB1*07-DQB1*02 showed an association trend with age of onset ($P = 0.0626$).

To investigate whether DRB1*07 may serve as a disease biomarker in LOMG, we compared other demographic characteristics and clinical aspects, between carriers ($n = 45$) and non-carriers ($n = 62$). All the analyzed variables did not differ between the two groups (Table S2).

Titin Abs were assayed in serum samples from 70 patients and were detected in 61.4% (43/70). No association was found between titin Ab positivity and age at onset or any other demographic or clinical features (Table S3). HLA-DRB1*07 was more frequent among titin-positive than -negative patients (11/43 vs 4/27, $P = 0.37$). The association of titin Abs with the haplotype DRB1*07-DQB1*02 reached borderline significance.
Figure 2. HLA Class II allele frequencies. The figure shows HLA DRB1 (A) and DQB1 (B) allele frequencies among LOMG patients and controls. Nominal p-values are indicated by asterisks: *P < 0.05, **P < 0.01, and ****P < 0.0001.
DISCUSSION

MG is a heterogeneous disease when considering associated Abs, thymus pathology and age of onset. As in other autoimmune diseases, HLA Class I and II antigens are the main predisposing factors. EOMG is strongly linked with the extended haplotype 8.1 (A1-B8-DQ2-DR3) in Caucasians, whereas MuSK-MG is associated with DQB1*05 and HLA-DRB1*14/DRB1*16 across different populations.

In LOMG, results have been far less consistent: initially, an association with HLA-B7 and DR2 was reported. More recently, this disease subtype was found to be strongly associated with DRB1*15:01 in a large sample of Norwegian MG patients ≥60 years at disease onset. Other studies, conducted in cohorts of different ethnicities and often of small size, reported mixed results: an association with DRB1*04 was found in Tunisians, with DRB1*01 in Portuguese, with DQA1*02:01, DQA1*01:02, and DQB1*06:02 in Turkish and with DQB1*05:02 and DRB1*16 in Italian MG patients.

In two GWAS, LOMG was associated with different signals. In the former, conducted in U.S. patients, there was an association with TNFRSF11A (rs4263037) and with rs9271871 in the DRB1-DQA1 intergenic region. The latter, performed in North European patients, found an association with DRB1*07:01, DRB1*15:01, and DQB1*02:02, which, however, did not reach genome-wide significance, whereas DRB1*03:01, DRB1*13:01, and DQB1*02:01 were found to be protective alleles.

In this study, we investigated HLA Class II associations in a large cohort of patients with AChR Ab positive, generalized, non-thymoma LOMG of single ethnicity. We found that HLA-DRB1*07 and, to a lesser extent, DRB1*14 increased the disease risk. DRB1*07 was previously associated with LOMG in Northern European patients: therefore, our results extend this association to South Europe. Regarding the DQB1 locus, Seldin and coworkers found that HLA DQB1*02 had opposite effects: DQB1*02:01 was protective, whereas DQB1*02:02 was a risk factor. The DQB1*02 was associated with LOMG in our study, that, however, was not powered to point out differences at the 4-digit level (data not shown). Overall, these results support the role of HLA DRB1*07 and DQB1*02 as risk alleles for LOMG across Caucasian populations.

Interestingly, we found a novel negative association with HLA-DRB1*11, suggesting a potential protective role of this allele, as already documented in other autoimmune diseases. Our data also confirmed the negative association of LOMG with HLA-DRB1*03, as reported in previous studies. This allele is part of the ancestral haplotype 8.1 (HLA A1-B8-D3-DQ2) and is strongly associated with EOMG, as well as other autoimmune diseases. The finding that EOMG and LOMG show opposite associations with DRB1*03, suggests multiple mechanisms leading to tolerance breakdown in these MG subtypes. These may include an interference in the determinants capture during self-antigen presentation, a modification of the selected self-epitopes by HLA alleles/haplotypes combinations, or a modulation of suppressor regulatory cells.

In our cohort, the DRB1*07-DQB1*02 haplotype showed the strongest association with the disease. Indeed, the conditional haplotype analysis revealed that neither DRB1*07 nor DQB1*02 independently predisposed to LOMG, whereas the entire haplotype conferred an increased risk. As a result of the increased frequency of these two alleles in our cohort, the LD between them was higher in patients than in controls (D' = 0.771 vs D' = 0.341). Based on these findings, it may be hypothesized that neither DRB1*07 nor DQB1*02 are the causative alleles. Rather, one or more other loci in linkage with

Table 2. HLA DRB1 and DQB1 allele frequencies and absolute numbers among patients and controls.

| Allele   | Frequency patients (%) | Frequency controls (%) | OR (95% C.I.) | P       |
|----------|------------------------|------------------------|---------------|---------|
| DRB1*01  | 0.0794 (17)            | 0.0925 (4091)          |               | NS      |
| DRB1*03  | 0.0234 (5)             | 0.036 (4140)           | 0.23 (0.10-0.56) | 7.89 x 10^-5 |
| DRB1*04  | 0.0841 (18)            | 0.0791 (3498)          |               | NS      |
| DRB1*07  | 0.2336 (50)            | 0.1249 (5524)          | 2.14 (1.55-2.94) | 1.08 x 10^-5 |
| DRB1*08  | 0.028 (6)              | 0.0311 (1375)          |               | NS      |
| DRB1*09  | 0.1121 (24)            | 0.1185 (5241)          |               | NS      |
| DRB1*10  | 0.0935 (20)            | 0.0563 (2490)          | 1.73 (1.09-2.74) | 0.0251  |
| DRB1*15  | 0.0841 (18)            | 0.0702 (3105)          |               | NS      |
| DRB1*16  | 0.0701 (15)            | 0.054 (2388)           |               | NS      |
| DQB1*02  | 0.2243 (48)            | 0.1955 (649)           | 1.57 (1.13-2.19) | 0.0095  |
| DQB1*03  | 0.3178 (68)            | 0.4111 (1716)          | 0.67 (0.50-0.90) | 0.0067  |
| DQB1*04  | 0.0187 (4)             | 0.0321 (134)           |               | NS      |
| DQB1*05  | 0.2664 (57)            | 0.2569 (1072)          |               | NS      |
| DQB1*06  | 0.1729 (37)            | 0.1445 (603)           |               | NS      |

OR, Odds ratio; C.I., confidence interval; NS, not significant.

(P = 0.0504). No associations of titin Abs with any other HLA allele or haplotype were found.
them on the same identified haplotype, such as HLA DQA1, a Class III gene or a gene located outside the HLA region, might be the actual predisposing factor to LOMG. Further studies are needed to clarify this point.

In addition, we found an association with DRB1*14-DQB1*05 and DRB1*15-DQB1*06 haplotypes. However, due to their weaker statistical association (p = 0.0012 and p = 0.0018, respectively) and their low frequency in the control population (0.0225 and 0.018 respectively), they were considered less likely to be predisposing factors.

Recently, an increased frequency of DRB1*16 and DQB1*05 was reported in an Italian cohort of 49 LOMG patients.18,19 We could not replicate these findings for DQB1*05 nor for DRB1*16 as single alleles, however we detected a weak association for the haplotype DRB1*16-DQB1*05 (0.039 in controls vs 0.07 in LOMG, P = 0.0494). Supposing that these two patient cohorts have the same genetic background, differences in inclusion criteria and age at onset cut-off may explain these divergent results.

Renton and co-workers found that the association of the TNFRSF11A single nucleotide polymorphism with MG increased in parallel with age of onset.21 Similarly, in our population, the DRB1*07 carrier frequency increased with the age at onset, and the median onset age was higher for homozygotes compared to heterozygotes and DRB1*07 non-carriers.

Giraud et al. reported the association of HLA-DR7 with titin Abs in non-thymoma French MG patients.32 As titin Abs are frequently detected in non-thymoma LOMG, this finding indirectly supports the association between DR7 and this MG subtype, possibly not detected in their study because of the low cut-off age (40 years). In line with this view, it was suggested that titin Abs and DR7 may better identify the LOMG subtype.39,40 However, in our study we did not find a significant association between HLA-DRB1*07 and titin Abs, rather an association trend for the haplotype DRB1*07-DQB1*02. The small number of patients tested for titin Abs likely underpowered our analysis. When clinical characteristics were analyzed, DRB1*07 carriers and non-carriers did not differ in disease severity, comorbidities, and response to therapies by univariate analysis. Furthermore, in our cohort, titin Abs were not associated with a more severe disease course, in line with other studies performed in non-Scandinavian populations,41 questioning their utility as a negative

Figure 3. Haplotype distribution between LOMG patients and controls. Haplotypes with frequencies <5% in both groups have been pooled together. These rare haplotypes are overall much less represented among patients, most likely due to the smaller sample size and to a numerical counting effect. Nominal p-values are indicated by asterisks: *P < 0.05, **P < 0.01, and ****P < 0.0001.
prognostic marker. These Abs are commonly detected in MG-thymoma, their production being most likely triggered by the tumour. On the other hand, the mechanisms leading to titin and RyR Abs production in LOMG are yet to be clarified.

One of the strongest points of our study was the inclusion of only non-thymoma, late-onset, generalized MG patients positive for AChR Abs in order to analyze a more homogenous population and possibly overcome the inherent heterogeneity of LOMG. The consecutive enrollment conceivably reduced the risk of selection bias. Moreover, the large size of our cohort and the use of publicly available controls, representative of the entire Italian population, reduced the risk of sampling error. On the other hand, a major study limitation is that we analyzed only DRB1 and DQB1 loci, hence it is possible that other loci, or genes, are responsible for or contribute to LOMG susceptibility. Unfortunately, neither HLA typing, nor titin Abs testing, provided valuable markers for disease prognosis and management. However, our data support the role of the haplotype HLA DRB1*07-DQB1*02 as a genetic risk factor for generalized AChR-positive non-thymoma LOMG in the Italian population. Further studies, based on a more comprehensive genomic analysis, are required to further clarify the predisposing factors in LOMG and their role in disease pathogenesis and management.

**Funding Information**

This study was funded by the “Linea D.1” grant of the Catholic University of Sacred Heart (Rome, Italy), grant code R4124500986, and by the Italian Ministry of Health Grant No. RF-2016-02364384.

**Authors’ Contribution**

GS: drafting of the manuscript; acquisition, analysis, and interpretation of data; critical revision of the manuscript for important intellectual content. LT, GM, MV, GDS, DD, MM: acquisition, analysis, and interpretation of data; critical revision of the manuscript for important intellectual content. AE: study concept and design; acquisition, analysis, and interpretation of data; critical revision of the manuscript for important intellectual content. CP: drafting of the manuscript; acquisition, analysis, and interpretation of data; critical revision of the manuscript for important intellectual content.

**Conflict of Interest**

The authors report no disclosures.

**References**

1. Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers 2019;5(1):30.
2. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015;14(10):1023–1036.
3. Somnier FE. Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 2005;65(6):928–930.
4. Matsui N, Nakane S, Nakagawa Y, et al. Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan. J Neurol Neurosurg Psychiatry 2009;80(10):1168–1171.
5. Casetta I, Fallica E, Govoni V, et al. Incidence of myasthenia gravis in the province of Ferrara: a community-based study. Neuroepidemiology 2004;23(6):281–284.
6. Cortés-Vicente E, Álvarez-Velasco R, Segovia S, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology 2020;94(11):e1171–e1180.
7. Romi F, Skeie GO, Aarli JA, Gilhus NE. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 2000;247(5):369–375.
8. Skeie GO, Mygland A, Aarli JA, Gilhus NE. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity 1995;20(2):99–104.
9. Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol 2000;57(11):1596–1600.
10. Fritze D, Herrman C Jr, Naeim F, et al. HL-A antigens in myasthenia gravis. Lancet 1974;1(7851):240–242.
11. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103(3):579–601.
12. Maniaol AH, Elsais A, Lorentzen AR, et al. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One 2012;7(5):e36603.
13. GregerSEN PK, Kosoy R, Lee AT, et al. Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann Neurol 2012;72(6):927–935.
14. Fekih-Mrissa N, Klai S, Zaouali J, et al. Association of HLA-DR/DQ polymorphism with myasthenia gravis in Tunisian patients. Clin Neurol Neurosurg 2013;115(1):32–36.
15. Santos E, Bettencourt A, da Silva AM, et al. HLA and age of onset in myasthenia gravis. Neuromuscul Disord 2017;27(7):650–654.
16. Saruhan-Direskeneli G, Kılıç A, Parman Y, et al. HLA-DQ polymorphism in Turkish patients with myasthenia gravis. Hum Immunol 2006;67(4–5):352–358.
17. Saruhan-Direskeneli G, Hughes T, Yilmaz V, et al. Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis. Clin Immunol 2016;166–167:81–88.

18. Massa R, Greco G, Testi M, et al. Thymomatous myasthenia gravis: novel association with HLA DQBI*05:01 and strengthened evidence of high clinical and serological severity. J Neurol 2019;266(4):982–989.

19. Testi M, Terracciano C, Guagnano A, et al. Association of HLA-DQBI*05:02 and DRBI*16 Alleles with Late-Onset, Nonthymomatous, AChR-Ab-Positive Myasthenia Gravis. Autoimmune Dis 2012;2012:541760.

20. Seldin MF, Alkhairy OK, Lee AT, et al. Genome-wide association study of late-onset myasthenia gravis: Confirmation of TNFRSF11A and identification of ZBTB10 and Three Distinct HLA Associations. Mol Med 2016;21(1):769–781.

21. Renton AE, Pliner HA, Provenzano C, et al. A genome-wide association study of late-onset myasthenia gravis: comparative analysis between the included cohort and total LOMG population treated at our Center.

22. Evoli A, Antonini G, Antozzi C, et al. Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol Sci 2019;40(6):1111–1124.

23. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55(1):16–23.

24. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2019.

25. Rendine S, Ferrero NM, Sacchi N, et al. Estimation of human leukocyte antigen class I and class II high-resolution allele and haplotype frequencies in the Italian population and comparison with other European populations. Hum Immunol 2012;73(4):399–404.

26. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68(4):978–989.

27. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81(3):559–575.

28. Bartocciioni E, Scuderi F, Augugliaro A, et al. HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 2009;72(2):195–197.

29. Niks EH, Kuk J, Boe BO, et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006;66(11):1772–1774.

30. Alahgholi-Hajibeizad M, Yilmaz V, Gülşen-Parman Y, et al. Association of HLA-DRB1*14, -DRBI*16 and -DQBI*05 with MuSK-myasthenia gravis in patients from Turkey. Hum Immunol 2017;79(12):1633–1635.

31. Kanai T, Uzawa A, Kawaguchi N, et al. HLA-DRB1*14 and DQBI*05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients. J Neurol Sci 2016;353(1):116–118.

32. Giraud M, Beaurain G, Yamamoto AM, et al. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 2001;57(9):1555–1560.

33. Di Sante G, Toluso B, Fedele AL, et al. Collagen specific T-cell repertoire and HLA-DR alleles: biomarkers of active refractory rheumatoid arthritis. EBioMedicine 2015;2(12):2037–2045.

34. Niu Z, Zhang P, Tong Y. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int J Rheum Dis 2015;18(1):17–28.

35. Bruijstens AL, Wong YYM, van Pelt DE, et al. HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population. Neurrol Neuroimmunol Neuroinflamm 2020;7(3).

36. Ge X, James EA, Reijonen H, Kwok WW. Differences in self-peptide binding between T1D-related susceptible and protective DR4 subtypes. J Autoimmun 2011;36(2):155–160.

37. Mangalam AK, Tanjea V, David CS. HLA class II molecules influence susceptibility versus protection in inflammatory diseases by determining the cytokine profile. J Immunol 2013;190(2):513–518.

38. Tsai S, Santamaria P. MHC class II polymorphisms, autoreactive T-cells, and autoimmunity. Front Immunol 2013;10(4):321.

39. Aarli JA. Myasthenia gravis in the elderly: Is it different? Ann N Y Acad Sci 2008;1132:238–243.

40. Aarli JA, Romi F, Skeie GO, Gilhus NE. Myasthenia gravis in individuals over 40. Ann N Y Acad Sci 2003;998:424–431.

41. Szczudlik P, Szyluk B, Lipowska M, et al. Antititin antibody in early- and late-onset myasthenia gravis. Autoimmun Rev 2014;13(01):229–233.

42. Yamamoto AM, Gajdos P, Eymard B, et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 2001;58(6):885–890.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Comparative analysis between the included cohort and total LOMG population treated at our Center.

Table S2. Comparative analysis of demographic and clinical features of DRB1*07 carriers and non-carriers.

Table S3. Comparative analysis of demographic and clinical features of titin Ab positive and negative patients.
Table S4. Haplotype frequencies in LOMG patients and controls.

Figure S1. Mean age at disease onset in patients carrying or not carrying the HLA-DRB1*07 allele. The average age at onset was 73.4 years among homozygotes for DRB1*07 (DRB1*07 H), 69.7 among heterozygotes (DRB1*07 HT), and 66.6 among patients not carrying any DRB1*07 allele (NO DRB1*07) (p = 0.0488). H = homozygote; HT = heterozygote; bars = standard mean errors.